Products
Zilovertamab Vedotin Biosimilar Antibody-Drug Conjugate (ROR1) for Research
Pre-made Zilovertamab Vedotin benchmark antibody (Whole mAb ADC, anti-ROR1 therapeutic antibody, Anti-NTRKR1/dJ537F10.1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1057-1mg | 1mg | 4635 |
| GMP-Bios-INN-1057-10mg | 10mg | |
| GMP-Bios-INN-1057-100mg | 100mg | |
| GMP-Bios-INN-1057-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zilovertamab Vedotin Biosimilar, Whole Mab Adc, Anti-Ror1 Antibody: Anti-NTRKR1/dJ537F10.1 therapeutic antibody Drug Conjugate |
| INN Name | Zilovertamab Vedotin |
| Target | ROR1 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | human |
| CH1 Isotype | IgG1 - kappa |
| VD LC | IgG1 - kappa |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Merck & Co., Inc. (Whitehouse Station NJ USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - ROR1
1. Protein Inactive tyrosine-protein kinase transmembrane receptor ROR1
2. Gene ROR1
3. Organism Homo sapiens (Human)
Function
Has very low kinase activity in vitro and is unlikely to function as a tyrosine kinase in vivo (PubMed:25029443).
Receptor for ligand WNT5A which activate downstream NFkB signaling pathway and may result in the inhibition of WNT3A-mediated signaling (PubMed:25029443, PubMed:27162350).
In inner ear, crucial for spiral ganglion neurons to innervate auditory hair cells (PubMed:27162350).
